Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
A Grim Reality Strikes Individuals Discontinuing GLP-1 Medications - Featured image
Health

A Grim Reality Strikes Individuals Discontinuing GLP-1 Medications

Dr. Adrian Vale, MD
Reviewed by Dr. Adrian Vale, MDInternal Medicine · Board-Certified Obesity Medicine
·January 4, 2026·2 min read

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Numerous individuals achieving weight reduction on GLP-1 agonists encounter challenges in ceasing the treatments, as appetite surges and weight rebounds. Studies indicate significant regain for those stopping, prompting some to view obesity as a chronic issue requiring ongoing medication. However, adopting healthier habits can help maintain losses post-treatment.

Share

Challenges in Discontinuing GLP-1 Treatments

A significant number of individuals who effectively shed pounds using Ozempic and similar GLP-1 agonist medications struggle to taper off the injections, as reported by the BBC. Hunger returns fiercely, causing weight to gradually increase once more, suggesting users may become reliant on these substances for life.

Tanya Hall, a Wegovy recipient unable to discontinue the medication, shared with the outlet: "Throughout my initial 38 years, I battled excess weight—now, I'm 38kg (83 pounds) lighter." She added, "This means a portion of me senses an attachment to continue, as it grants me a sense of command over my situation."

Studies support this, demonstrating that those halting these drugs frequently regain a substantial portion of their lost mass. Celebrities such as Oprah have expressed intentions to remain on them perpetually, as she revealed to People Magazine recently. The takeaway is that numerous individuals might need to manage obesity as a persistent ailment, relying on these drugs indefinitely.

"It will be a permanent commitment," Oprah stated. "I take medication for hypertension, and stopping it elevates my blood pressure. I've come to understand the same applies here—I require it."

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

For those who successfully stop, they typically regain roughly two-thirds of their shed pounds, based on investigations by Ozempic producer Novo Nordisk. Dr. Hussain Al-Zubaidi informed the BBC that he has observed patients recovering 60 to 80 percent of their prior weight losses.

Despite appearances of futility, there is optimism, according to Al-Zubaidi. He recommends developing an "exit plan" involving the adoption of better lifestyle adjustments during treatment. These changes can preserve weight reduction after fully stopping the medications. Health tracking apps like Shotlee can assist in monitoring these new habits effectively.

This proved true for Ellen Ogley, who recounted to the BBC losing 48.5 pounds on Eli Lilly's GLP-1 drug Mounjaro. During her time on it, she cultivated improved dietary routines and integrated physical activity. Even after several months without the medication, she has sustained her progress.

"I aim to inform others that existence beyond Mounjaro can indeed endure," she remarked.

Source Information

Originally published by Yahoo! Health.Read the original article →

Read next

Keep exploring

Same topic: GLP-1 medications

All GLP-1 medications articles →
Serena Williams Champions GLP-1s: Ads Air Amidst Tennis Comeback
Health & Wellness

Serena Williams Champions GLP-1s: Ads Air Amidst Tennis Comeback

Tennis legend Serena Williams is making waves both on and off the court. As she returns to professional tennis, advertisements featuring her advocacy for GLP-1 medications are set to air, highlighting a significant cultural moment for weight management therapies.

6 min read
GLP-1 Drugs & Your Knees: New Research on Joint Health
Health & Wellness

GLP-1 Drugs & Your Knees: New Research on Joint Health

Discover how GLP-1 medications, known for weight loss, may also significantly reduce the need for knee replacement surgery. This article delves into the latest research and its implications for joint health.

7 min read
Wegovy & Mounjaro Boom Fuels Peptide Production Surge for GLP-1 Drugs
Pharmaceutical Manufacturing & Innovation

Wegovy & Mounjaro Boom Fuels Peptide Production Surge for GLP-1 Drugs

The unprecedented demand for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound is triggering a significant global expansion in peptide manufacturing. Learn how key players are investing billions to meet the surging need for these life-changing therapies.

7 min read

More in Health

Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?
Health & Wellness

Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?

Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.

7 min read
Retatrutide: The Next Frontier in Weight Loss and Its Profound Implications
Health & Wellness

Retatrutide: The Next Frontier in Weight Loss and Its Profound Implications

Eli Lilly's experimental drug retatrutide is showing unprecedented weight loss results, pushing the boundaries of what's possible. But with great power comes great responsibility, and doctors are urging caution.

7 min read
Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds
Health & Wellness

Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds

A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.

7 min read
Share this article
  1. Home
  2. Blog
  3. A Grim Reality Strikes Individuals Discontinuing GLP-1 Medications
Dr. Adrian Vale, MD — Internal Medicine · Board-Certified Obesity Medicine
Medically reviewed

Dr. Adrian Vale, MD

Internal Medicine · Board-Certified Obesity Medicine

Dr. Adrian Vale is a board-certified internal medicine physician with a clinical focus on obesity medicine and metabolic health. He reviews Shotlee guides and articles on GLP-1 medications, peptide therapy, and weight-management protocols for clinical accuracy.

View all articles reviewed by Dr. Adrian Vale, MD
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community